This study showed that supplementation of steviol glycosides (stevioside and rebaudioside A) does not improve blood glucose, insulin, insulin resistance indices, or antioxidant biomarkers, but normalize hyperlipidemia, significantly improve liver and kidney function indices, affect feed intake and some appetite control biomarkers, and attenuate damage in pancreatic, hepatic, and renal tissue in diabetic rats. The gene discussed is INS; the disease is hyperlipidemia.